SDHB-Associated Pheochromocytomas: What is Their Clinical Behavior?

Introduction Germline pathogenic variants in succinate dehydrogenase subunit B ( SDHB ) cause paraganglioma/pheochromocytoma syndrome type 4 (PGL-4). SDHB -associated pheochromocytomas (PCC) are thought to be rare and little data exist about their clinical behavior. Patients and methods Retrospective review of patients treated (1993–2023) at a tertiary cancer center for SDHB -associated PCC. Clinical and demographic variables were retrieved to characterize disease-free survival, disease progression, and overall survival. Results In total, 90 SDHB -carriers were identified, 18% had PCC ( n = 16). Median age at diagnosis of was 40 (19–76) years, 50% ( n = 8) of patients were male, 25% ( n = 4) had distant metastasis (DM) at diagnosis, and 13% ( n = 2) had synchronous PGL. No patients had bilateral disease, and 94% of patients underwent surgery as initial treatment with a curative intent in 75%. Overall, 64% of patients underwent open resection. Recurrence occurred in 77% of patients ( n = 10), 75% in minimally invasive surgery (MIS) versus 77% open, p = 0.63. Bone was the most common site of DM (100%, n = 13). Metaidobenzyleguanidine (MIBG) imaging was performed in 69% of patients, 91% of which were positive. Median time from surgery until recurrence was 36 months (1–295 months). Radiation therapy was the most common adjuvant treatment (44%) followed by Iobenguane I-131 (31%) and systemic therapy (31%). Median follow-up time was 56 months (1–408 months). Overall, 33% of patients were alive, 19% of patients were disease-free, and 50% of the patients with DM had stable disease at last follow-up. Conclusions Overall, 18% of germline SDHB mutation-carriers were diagnosed with PCC, all of which were unilateral. SDHB -associated PCC was associated with advanced and recalcitrant disease and was often MIBG positive. More studies are needed to better understand the clinical behavior of PCC in PGL-4.